Health Canada approves Medivation (MDVN) and Astellas' (ALPMY.PK) XTANDI (enzalutamide) for the...

|By:, SA News Editor

Health Canada approves Medivation (MDVN) and Astellas' (ALPMY.PK) XTANDI (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. (Previous: XTANDI submitted to Japanese regulators; XTANDI sales rise)